Close Menu
September 02, 2020
Sponsored by
ACD

Spatial Profiling to Assess a Novel Gene Therapy in a Mouse Model of a Rare Genetic Disorder

GenomeWebinar

Scientist II,
Ultragenyx Pharmaceutical

This webinar will discuss the use of digital spatial profiling to test a gene therapy for CDKL5 deficiency disorder (CDD), a rare X-linked neurodevelopmental disease that causes severe seizures, global developmental delay, and limits a patient’s ability to communicate.

Maggie Wright of Ultragenyx Pharmaceutical will outline her team’s approach to testing a gene therapy in a mouse model of CDD:

  • Adolescent CDKL5-/Y and CDKL5-/+ mice were administered the gene therapy AAV9-SYN-hCDKL5 via the intracerebral ventricular space
  • Distribution of the vector-derived hCDKL5 mRNA was assayed in the brain of these mice via RNAScope
  • Behavioral phenotypes of these treated mice were tested to determine efficacy of the treatment
Sponsored by

According to the Wall Street Journal, the Food and Drug Administration may soon issue an Emergency Use Authorization for convalescent plasma to treat COVID-19 patients.

Minnesota police have used genetic genealogy to make an arrest in a 1986 cold case, reports NBC News.

Researchers have used CRISPR-Cas9 to efficiently target a cephalopod pigmentation gene, as they report in Current Biology.

In Science this week: chromatin accessibility of microglia during fetal development, and more.

Aug
19
Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.

Aug
24
Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug
25
Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Aug
27
Sponsored by
Cellecta

Over 70 percent of breast cancers are estrogen receptor positive and are treated with endocrine therapy.